The Toronto-based drugmaker's revenue held steady, helped by stronger performance from its Colombian operations.

The struggling psychedelics firm abandoned direct patient care in favor of developing tech for insurance reimbursement and ...

A new credit facility provided $8 million in net proceeds for growth initiatives ahead of a planned mid-2025 integration with ...

While broader real estate stocks rallied on the Federal Reserve’s latest rate cut, with the Real Estate Select Sector SPDR ...

The firm expects to report its 12-month phase 2 data next week, with topline results from a phase 3 trial anticipated in 2026 ...

California-based Lowell Farms (CSE: LOWL) (OTCQX: LOWLF) this week reported a net loss of $3.6 million for the third quarter, ...

During the third quarter, 4Front retained Canaccord Genuity Corp. to help with an internal reorganization, particularly ...

Ditching cannabis growing tech for hemp-based drinks marks a new era for the firm under its new GTI leadership.

Tilt also reported a net loss of $12.6 million in the quarter versus a net loss of $8.7 million in the prior year period. At ...

Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

Regulators outlined recommendations and rules related to creating a safe working environment for those working with cannabis.

A coalition of 120 craft cannabis farmers in New York filed suit against the state’s marijuana regulators this week, claiming ...